{"id":"W2099088585","doi":"10.1200/jco.2008.20.1293","title":"Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2189,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Pfizer Canada; Genentech; GlaxoSmithKline; American Society of Clinical Oncology; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Hazard ratio; Discontinuation; Alpha interferon; Adverse effect; Clinical endpoint; Gastroenterology; Log-rank test; Progression-free survival; Oncology; Urology; Proportional hazards model; Randomized controlled trial; Confidence interval; Interferon; Overall survival; Immunology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002276477,0.0004674793,0.001210196,0.0002419173,0.0001940795,0.0005515926,0.0003125574,0.00046901,0.001654634],"category_scores_gemma":[0.002309037,0.0001551999,0.001682736,0.0002807314,0.0002371314,0.0003777179,0.000202722,0.00109095,0.0002020027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005688097,"about_ca_system_score_gemma":0.0004701593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005738072,"about_ca_topic_score_gemma":0.001513624,"domain_scores_codex":[0.9991072,0.0004887452,0.0000727001,0.0001031754,0.0001600563,0.00006818609],"domain_scores_gemma":[0.9985365,0.0005348324,0.0005688823,0.00007188402,0.0001147385,0.0001731808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.675386,0.001892891,0.07353703,0.002035528,0.01029095,0.0002305151,0.0001569448,0.003780112,0.007732028,0.0001529756,0.004041505,0.2207637],"study_design_scores_gemma":[0.184882,0.2041999,0.5589572,0.0004649495,0.02666723,0.00158803,0.0001372208,0.00631946,0.00730718,0.0005366979,0.008842248,0.00009790665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751652,0.0219363,0.0003928032,0.0004681314,0.0001485081,0.0001099799,0.0007248135,0.00003443786,0.0010197],"genre_scores_gemma":[0.9944589,0.00280952,0.0002939753,0.0003495261,0.0001826625,0.00009480191,0.001288572,0.000007393316,0.0005146036],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002276477,"threshold_uncertainty_score":0.0120393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1019284234891843,"score_gpt":0.387397130270231,"score_spread":0.2854687067810467,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}